Syros Pharmaceuticals Stock Sinks As Pivotal Blood Cancer Trial Flunks, Triggers Loan Default - Syros Pharmaceuticals ( NASDAQ:SYRS )
Syros Pharmaceuticals Inc SYRS revealed on Tuesday that the SELECT-MDS-1 Phase 3 trial of tamibarotene did not meet its primary endpoint of complete response rate. The trial assessed tamibarotene in combination with azacitidine in newly diagnosed higher-risk myelodysplastic syndrome ( HR-MDS ) ...
| Ticker |
Sentiment |
Impact |
|
SYRS
|
Neutral
|
48 %
|
|
BMY
|
Neutral
|
20 %
|
